))
Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
Manage episode 414417890 series 3381434
Innhold levert av ReachMD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av ReachMD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
CME credits: 0.25
Valid until: 09-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/preventing-disease-recurrence-adjuvant-therapy-stage-iibiic-melanoma/15392/
The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.=
…
continue reading
Valid until: 09-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/preventing-disease-recurrence-adjuvant-therapy-stage-iibiic-melanoma/15392/
The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.=
682 episoder
Del
